Evogene Ltd 6-K, filed Feb 5, 2025
Evogene Ltd. (EVGN)
6-K
2025-02-05
For: 2025-02-05
View Original
Added on
April 05, 2026
About this 6-K
Evogene Ltd filed this 6-K on February 5, 2025.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2025
Commission File Number: 001-36187
EVOGENE LTD.
(Translation of Registrant’s Name into English)
13 Gad Feinstein Street, Park Rehovot, Rehovot
7638517, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
CONTENTS
On February 5, 2025, Evogene Ltd. (the “Company”) convened its Special General Meeting of Shareholders (the “Annual Meeting”), however, it was adjourned for one week to the same day, time and place due to lack of quorum. Accordingly, the Company’s Special General Meeting will be reconvened on Wednesday, February 12, 2025 at 3:00 p.m.
(Israel time), at the executive offices of the Company, 13 Gad Feinstein Street, Park Rehovot, Rehovot, Israel.
The content of this Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the registration statements on Form F-3 (File No. 333-277565) and on Form S-8 (SEC File Nos. 333-193788, 333-201443, 333-203856 and 333-259215) of the
Company, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Date: February 5, 2025 |
EVOGENE LTD.
(Registrant) By: /s/ Yaron Eldad Yaron Eldad Chief Financial Officer |